Publikation:

Selective metabolic regulations by p53 mutant variants in pancreatic cancer

Lade...
Vorschaubild

Dateien

Caporali_2-1tehpc162l81e7.pdf
Caporali_2-1tehpc162l81e7.pdfGröße: 5.98 MBDownloads: 7

Datum

2024

Herausgeber:innen

Kontakt

ISSN der Zeitschrift

Electronic ISSN

ISBN

Bibliografische Daten

Verlag

Schriftenreihe

Auflagebezeichnung

ArXiv-ID

Internationale Patentnummer

Link zur Lizenz

Angaben zur Forschungsförderung

European Union (EU): 964537
Deutsche Forschungsgemeinschaft (DFG): TRR353

Projekt

Open Access-Veröffentlichung
Open Access Gold
Core Facility der Universität Konstanz

Gesperrt bis

Titel in einer weiteren Sprache

Publikationstyp
Zeitschriftenartikel
Publikationsstatus
Published

Erschienen in

Journal of Experimental & Clinical Cancer Research. Springer. 2024, 43(1), 310. eISSN 1756-9966. Verfügbar unter: doi: 10.1186/s13046-024-03232-3

Zusammenfassung

Background Approximately half of all human cancers harbour mutations in the p53 gene, leading to the generation of neomorphic p53 mutant proteins. These mutants can exert gain-of-function (GOF) effects, potentially promoting tumour progression. However, the clinical significance of p53 GOF mutations, as well as the selectivity of individual variants, remains controversial and unclear. Methods To elucidate the metabolic regulations and molecular underpinnings associated with the specific p53 R270H and p53 R172H mutant variants (the mouse equivalents of human p53 R273H and p53 R175H , respectively), we employed a comprehensive approach. This included integrating global metabolomic analysis with epigenomic and transcriptomic profiling in mouse pancreatic cancer cells. Additionally, we assessed metabolic parameters such as oxygen consumption rate and conducted analyses of proliferation and cell–cell competition to validate the biological impact of metabolic changes on pancreatic ductal adenocarcinoma (PDAC) phenotype. Our findings were further corroborated through analysis of clinical datasets from human cancer cohorts. Results
Our investigation revealed that the p53 R270H variant, but not p53 R172H , sustains mitochondrial function and energy production while also influencing cellular antioxidant capacity. Conversely, p53 R172H , while not affecting mitochondrial metabolism, attenuates the activation of pro-tumorigenic metabolic pathways such as the urea cycle. Thus, the two variants selectively control different metabolic pathways in pancreatic cancer cells. Mechanistically, p53 R270H induces alterations in the expression of genes associated with oxidative stress and reduction in mitochondrial respiration. In contrast, p53 R172H specifically impacts the expression levels of enzymes involved in the urea metabolism. However, our analysis of cell proliferation and cell competition suggested that the expression of either p53 R270H or p53 R172H does not influence confer any selective advantage to this cellular model in vitro. Furthermore, assessment of mitochondrial priming indicated that the p53 R270H -driven mitochondrial effect does not alter cytochrome c release or the apoptotic propensity of pancreatic cancer cells. Conclusions Our study elucidates the mutant-specific impact of p53 R270H and p53 R172H on metabolism of PDAC cancer cells, highlighting the need to shift from viewing p53 mutant variants as a homogeneous group of entities to a systematic assessment of each specific p53 mutant protein. Moreover, our finding underscores the importance of further exploring the significance of p53 mutant proteins using models that more accurately reflect tumor ecology.

Zusammenfassung in einer weiteren Sprache

Fachgebiet (DDC)
570 Biowissenschaften, Biologie

Schlagwörter

Konferenz

Rezension
undefined / . - undefined, undefined

Forschungsvorhaben

Organisationseinheiten

Zeitschriftenheft

Zugehörige Datensätze in KOPS

Zitieren

ISO 690CAPORALI, Sabrina, Alessio BUTERA, Alessia RUZZA, Carlotta ZAMPIERI, Ivana CELARDO, Ian U. KOUZEL, Andreas J. GRUBER, Thomas BRUNNER, Marcel LEIST, Ivano AMELIO, 2024. Selective metabolic regulations by p53 mutant variants in pancreatic cancer. In: Journal of Experimental & Clinical Cancer Research. Springer. 2024, 43(1), 310. eISSN 1756-9966. Verfügbar unter: doi: 10.1186/s13046-024-03232-3
BibTex
@article{Caporali2024-11-26Selec-71503,
  title={Selective metabolic regulations by p53 mutant variants in pancreatic cancer},
  year={2024},
  doi={10.1186/s13046-024-03232-3},
  number={1},
  volume={43},
  journal={Journal of Experimental & Clinical Cancer Research},
  author={Caporali, Sabrina and Butera, Alessio and Ruzza, Alessia and Zampieri, Carlotta and Celardo, Ivana and Kouzel, Ian U. and Gruber, Andreas J. and Brunner, Thomas and Leist, Marcel and Amelio, Ivano},
  note={Article Number: 310}
}
RDF
<rdf:RDF
    xmlns:dcterms="http://purl.org/dc/terms/"
    xmlns:dc="http://purl.org/dc/elements/1.1/"
    xmlns:rdf="http://www.w3.org/1999/02/22-rdf-syntax-ns#"
    xmlns:bibo="http://purl.org/ontology/bibo/"
    xmlns:dspace="http://digital-repositories.org/ontologies/dspace/0.1.0#"
    xmlns:foaf="http://xmlns.com/foaf/0.1/"
    xmlns:void="http://rdfs.org/ns/void#"
    xmlns:xsd="http://www.w3.org/2001/XMLSchema#" > 
  <rdf:Description rdf:about="https://kops.uni-konstanz.de/server/rdf/resource/123456789/71503">
    <dc:rights>Attribution 4.0 International</dc:rights>
    <foaf:homepage rdf:resource="http://localhost:8080/"/>
    <dspace:isPartOfCollection rdf:resource="https://kops.uni-konstanz.de/server/rdf/resource/123456789/28"/>
    <dc:creator>Leist, Marcel</dc:creator>
    <dcterms:rights rdf:resource="http://creativecommons.org/licenses/by/4.0/"/>
    <bibo:uri rdf:resource="https://kops.uni-konstanz.de/handle/123456789/71503"/>
    <dc:creator>Caporali, Sabrina</dc:creator>
    <dc:contributor>Butera, Alessio</dc:contributor>
    <dcterms:title>Selective metabolic regulations by p53 mutant variants in pancreatic cancer</dcterms:title>
    <dcterms:abstract>Background
Approximately half of all human cancers harbour mutations in the p53 gene, leading to the generation of neomorphic p53 mutant proteins. These mutants can exert gain-of-function (GOF) effects, potentially promoting tumour progression. However, the clinical significance of p53 GOF mutations, as well as the selectivity of individual variants, remains controversial and unclear.
Methods
To elucidate the metabolic regulations and molecular underpinnings associated with the specific p53 &lt;sup&gt;R270H&lt;/sup&gt; and p53 &lt;sup&gt;R172H &lt;/sup&gt;mutant variants (the mouse equivalents of human p53 &lt;sup&gt;R273H&lt;/sup&gt; and p53 &lt;sup&gt;R175H&lt;/sup&gt; , respectively), we employed a comprehensive approach. This included integrating global metabolomic analysis with epigenomic and transcriptomic profiling in mouse pancreatic cancer cells. Additionally, we assessed metabolic parameters such as oxygen consumption rate and conducted analyses of proliferation and cell–cell competition to validate the biological impact of metabolic changes on pancreatic ductal adenocarcinoma (PDAC) phenotype. Our findings were further corroborated through analysis of clinical datasets from human cancer cohorts.
Results          
Our investigation revealed that the p53 &lt;sup&gt;R270H&lt;/sup&gt; variant, but not p53 &lt;sup&gt;R172H&lt;/sup&gt; , sustains mitochondrial function and energy production while also influencing cellular antioxidant capacity. Conversely, p53 &lt;sup&gt;R172H&lt;/sup&gt; , while not affecting mitochondrial metabolism, attenuates the activation of pro-tumorigenic metabolic pathways such as the urea cycle. Thus, the two variants selectively control different metabolic pathways in pancreatic cancer cells. Mechanistically, p53 &lt;sup&gt;R270H&lt;/sup&gt; induces alterations in the expression of genes associated with oxidative stress and reduction in mitochondrial respiration. In contrast, p53&lt;sup&gt; R172H&lt;/sup&gt; specifically impacts the expression levels of enzymes involved in the urea metabolism. However, our analysis of cell proliferation and cell competition suggested that the expression of either p53 R270H or p53 R172H does not influence confer any selective advantage to this cellular model in vitro. Furthermore, assessment of mitochondrial priming indicated that the p53 &lt;sup&gt;R270H&lt;/sup&gt; -driven mitochondrial effect does not alter cytochrome c release or the apoptotic propensity of pancreatic cancer cells.
Conclusions
Our study elucidates the mutant-specific impact of p53 &lt;sup&gt;R270H&lt;/sup&gt; and p53 &lt;sup&gt;R172H&lt;/sup&gt; on metabolism of PDAC cancer cells, highlighting the need to shift from viewing p53 mutant variants as a homogeneous group of entities to a systematic assessment of each specific p53 mutant protein. Moreover, our finding underscores the importance of further exploring the significance of p53 mutant proteins using models that more accurately reflect tumor ecology.</dcterms:abstract>
    <dc:contributor>Ruzza, Alessia</dc:contributor>
    <dcterms:available rdf:datatype="http://www.w3.org/2001/XMLSchema#dateTime">2024-11-29T11:14:20Z</dcterms:available>
    <dc:contributor>Celardo, Ivana</dc:contributor>
    <dc:contributor>Caporali, Sabrina</dc:contributor>
    <dc:contributor>Amelio, Ivano</dc:contributor>
    <dc:contributor>Brunner, Thomas</dc:contributor>
    <dc:creator>Zampieri, Carlotta</dc:creator>
    <dcterms:hasPart rdf:resource="https://kops.uni-konstanz.de/bitstream/123456789/71503/1/Caporali_2-1tehpc162l81e7.pdf"/>
    <dc:creator>Kouzel, Ian U.</dc:creator>
    <dc:creator>Celardo, Ivana</dc:creator>
    <dc:language>eng</dc:language>
    <dspace:hasBitstream rdf:resource="https://kops.uni-konstanz.de/bitstream/123456789/71503/1/Caporali_2-1tehpc162l81e7.pdf"/>
    <dcterms:issued>2024-11-26</dcterms:issued>
    <dc:contributor>Kouzel, Ian U.</dc:contributor>
    <dc:creator>Butera, Alessio</dc:creator>
    <dc:creator>Gruber, Andreas J.</dc:creator>
    <dc:creator>Brunner, Thomas</dc:creator>
    <dc:contributor>Leist, Marcel</dc:contributor>
    <dcterms:isPartOf rdf:resource="https://kops.uni-konstanz.de/server/rdf/resource/123456789/28"/>
    <dc:creator>Amelio, Ivano</dc:creator>
    <dc:date rdf:datatype="http://www.w3.org/2001/XMLSchema#dateTime">2024-11-29T11:14:20Z</dc:date>
    <dc:creator>Ruzza, Alessia</dc:creator>
    <dc:contributor>Zampieri, Carlotta</dc:contributor>
    <dc:contributor>Gruber, Andreas J.</dc:contributor>
    <void:sparqlEndpoint rdf:resource="http://localhost/fuseki/dspace/sparql"/>
  </rdf:Description>
</rdf:RDF>

Interner Vermerk

xmlui.Submission.submit.DescribeStep.inputForms.label.kops_note_fromSubmitter

Kontakt
URL der Originalveröffentl.

Prüfdatum der URL

Prüfungsdatum der Dissertation

Finanzierungsart

Kommentar zur Publikation

Allianzlizenz
Corresponding Authors der Uni Konstanz vorhanden
Internationale Co-Autor:innen
Universitätsbibliographie
Ja
Begutachtet
Ja
Diese Publikation teilen